You are using an outdated browser. Please upgrade your browser to improve your experience and security.

What is VYXEOS?

VYXEOS (vix-e-ose) is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

You can learn more about VYXEOS by watching this video.

How is VYXEOS different?

VYXEOS is an advancement from traditional chemotherapy for adults with certain types of newly-diagnosed sAML. It is the only treatment for these types of AML that combines 2 currently used, effective chemotherapies into tiny, bubble-like carriers called liposomes, which carry the drugs to the bone marrow. The liposomes are taken up by leukemia cells (blasts) to a greater extent than by normal cells. Once inside, the liposomes release the drugs to help kill the blasts. This type of technology, combining 2 drugs within a liposome, is the first of its kind in AML treatment.

IV Bag icon

Chemotherapy solutions can be various colors. The VYXEOS solution is purple.

WHAT IS VYXEOS?

VYXEOS is a prescription intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders, have a specific genetic mutation, or have certain abnormal blood cells (also called AML with myelodysplasia-related changes, AML-MRC).

IMPORTANT SAFETY INFORMATION

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.